ANALYSIS OF CLINICAL AND DEMOGRAPHIC INDICATORS OF PATIENTS WITH PARKINSON'S DISEASE IN THE SOUTHERN REGION OF KAZAKHSTAN

Author(s): Abdraimova S.O, Arykbayeva G.M, Zharkinbekova N.A

DOI: 10.34689/SH.2024.26.1.004

Introduction. Parkinson's disease (PD) is a neurodegenerative progressive disease of the brain, leading to a decrease in the quality of life and further to disability of the patient. Given the steady increase in the number of patients with PD, the problem is becoming a pressing issue worldwide. According to the data of the Republican Centers of Е-health of the Ministry of Health of the Kazakhstan for Shymkent city and Turkestan region there is an annual increase in the prevalence of PD by 15-20%. Aim. To study clinical and demographic parameters of patients with PD in the Southern region of Kazakhstan. Materials and Methods. A cross-sectional one-stage cohort study of patients from the Southern region of Kazakhstan was conducted. The Unified PD Rating Scale (MDS-UPDRS) revised by the Movement Disorders Society [19] was used to assess motor and non-motor disorders, and the Hоehn-Yahr scale was used to assess the clinical stage. In statistical data processing, the mean, standard deviation (M±SD), or median were calculated. The law of distribution was checked using the Kolmogorov-Smirnov test when quantitative variables were analyzed, and the two-way Spearman rank correlation analysis was also used. Differences were considered statistically significant at p˂0.05. Results. 450 patients participated in the study: 36% (n=162) of urban residents and 64% of rural residents (n=288). There was a predominance of women among both urban and rural residents (57.4% and 55.2%) and patients in the age category 60-69 years (38.9% and 34.3%, respectively). The debut of the disease in the whole studied category was 50-59 and 60-69 years old. The correlation analysis of the studied revealed positive significant correlations between Hoehn-Yahr stages and four sections of the UPDRS scale (p<0.001). The severity of the disease increased with increasing UPDRS scale scores, confirming PD. Conclusion. Clinical and demographic analysis of PD in the Southern region of Kazakhstan was carried out for the first time. According to the data of the study, the indicators of the sample analyzed by us, such as average age, average duration of the disease, disease debut, coincide with the data of most domestic and foreign authors. Prospective studies performed in a particular region with the creation of a unified register of patients with PD is extremely important from both scientific and practical points of view.

Saltanat O. Abdraimova1, https://orcid.org/0000-0003-0162-2330 Gulnur M. Arykbayeva1, Nazira A. Zharkinbekova1, https://orcid.org/0000-0002-5069-1562 1 South Kazakhstan Medical Academy, Department of Neurology, Psychiatry, Rehabilitation and Neurosurgery, Shymkent, Republic of Kazakhstan.

1. Абдраимова С. О., Жаркинбекова Н. А. Факторы риска развития болезни Паркинсона в Южном регионе Казахстана // Наука и Здравоохранение. 2023. 2 (Т.25). С. 95–103. doi 10.34689/SH.2023.25.2.014 2. Информационное письмо 38/15 от 29.03.2023 г. Туркестанского областного филиала Республиканского Государственного предприятия на праве хозяйственного введения «Национальный Научный Центр Развития Здравоохранения имени С. Каирбековой» Министерства Здравоохранения Республики Казахстан. 3. Федорова Н.В., Омарова С.М. Леводопа-индуцированные дискинезии при болезни Паркинсона: фармакотерапия и нейрохирургическое лечение // Нервные болезни. 2017. №1. С.22-30. 4. Abbas M.M., Xu Z., Tan L.C.S. Epidemiology of Parkinson's Disease-East Versus West // Mov Disord Clin Pract. 2017 Dec 22;5(1):14-28. doi: 10.1002/mdc3.12568. PMID: 30363342; PMCID: PMC6174379 5. Aradi S.D., Hauser R.A. Medical Management and Prevention of Motor Complications in Parkinson's Disease // Neurotherapeutics. 2020 Oct;17(4):1339-1365. doi: 10.1007/s13311-020-00889-4. PMID: 32761324; PMCID: PMC7851275. 6. Ascherio A., Schwarzschild M.A. The epidemiology of Parkinson's disease: risk factors and prevention // Lancet Neurol. 2016 Nov;15(12):1257-1272. doi: 10.1016/S1474-4422(16)30230-7. Epub 2016 Oct 11. PMID: 27751556. 7. Balestrino R., Schapira A.H.V. Parkinson disease // Eur J Neurol. 2020 Jan. 27(1):27-42. doi: 10.1111/ene.14108. Epub 2019 Nov 27. PMID: 31631455. 8. Beitz J.M. Parkinson's disease: a review // Front Biosci (Schol Ed). 2014 Jan 1;6(1):65-74. doi: 10.2741/s415. PMID: 24389262. 9. Bloem B.R., Okun M.S., Klein C. Parkinson's disease // Lancet. 2021 Jun 12. 397(10291):2284-2303. doi: 10.1016/S0140-6736(21)00218-X. Epub 2021 Apr 10. PMID: 33848468. 10. Braak H., Del Tredici K., Rüb U., de Vos R.A., Jansen Steur E.N., Braak E. Staging of brain pathology related to sporadic Parkinson's disease // Neurobiol Aging. 2003 Mar-Apr. 24(2):197-211. doi: 10.1016/s0197-4580(02)00065-9. PMID: 12498954. 11. Cagac A. Farming, well water consumption, rural living, and pesticide exposure in early life as the risk factors for Parkinson disease in Iğdır province // Neurosciences. 2020. 25, 129–135. doi:10.17712/nsj.2020.2.20190104. 12. Cerri S., Mus L., Blandini F. Parkinson's Disease in Women and Men: What's the Difference? // J Parkinsons Dis. 2019. 9(3):501-515. doi: 10.3233/JPD-191683. PMID: 31282427. PMCID: PMC6700650. 13. Chia S.J., Tan E.K., Chao Y.X. Historical Perspective: Models of Parkinson’s Disease // International Journal of Molecular Sciences. 2020. 21, 2464. 14. Goetz C.G., Poewe W., Rascol O., Sampaio C., Stebbins G.T., Counsell C., Giladi N., Holloway R.G., Moore C.G., Wenning G.K., Yahr M.D., Seidl L. Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations // Mov Disord. 2004 Sep.19(9):1020-8. doi: 10.1002/mds.20213. PMID: 15372591. 15. Hayes M.T. Parkinson's Disease and Parkinsonism. Am J Med. 2019 Jul. 132(7):802-807. doi: 10.1016/j.amjmed.2019.03.001. Epub 2019 Mar 16. PMID: 30890425. 16. Jurado-Coronel J.C, Cabezas R., Ávila Rodríguez M.F., Echeverria V., García-Segura L.M., Barreto G.E. Sex differences in Parkinson's disease: Features on clinical symptoms, treatment outcome, sexual hormones and genetics // Front Neuroendocrinol. 2018 Jul. 50:18-30. doi: 10.1016/j.yfrne.2017.09.002. Epub 2017 Sep 30. PMID: 28974386. 17. Lee A., Gilbert R.M. Epidemiology of Parkinson Disease // Neurol Clin. 2016 Nov. 34(4):955-965. doi: 10.1016/j.ncl.2016.06.012. Epub 2016 Aug 18. PMID: 27720003. 18. Meoni S., Macerollo A., Moro E. Sex differences in movement disorders // Nat Rev Neurol. 2020 Feb;16(2):84-96. doi: 10.1038/s41582-019-0294-x. Epub 2020 Jan 3. PMID: 31900464. 19. Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease. The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations // Mov Disord. 2003 Jul. 18(7):738-50. doi: 10.1002/mds.10473. PMID: 12815652. 20. Post B., Van Den Heuvel L., Van Prooije T., Van Ruissen X., Van De Warrenburg B., Nonnekes J. Young Onset Parkinson’s Disease: A Modern and Tailored Approach // Journal of Parkinson's Disease 2020. 10. S29–S36. 21. Postuma R.B., Berg D., Stern M., Poewe W., Olanow C.W., et al. MDS clinical diagnostic criteria for Parkinson's disease // Movement Disorders 2015. 30, 1591–1601. doi:10.1002/mds.26424 22. Pringsheim T., Jette N., Frolkis A., Steeves T.D. The prevalence of Parkinson's disease: a systematic review and meta-analysis // Mov Disord. 2014 Nov. 29(13):1583-90. doi: 10.1002/mds.25945. Epub 2014 Jun 28. PMID: 24976103. 23. Reich S.G., Savitt J.M. Parkinson's Disease // Med Clin North Am. 2019 Mar. 103(2):337-350. doi: 10.1016/j.mcna.2018.10.014. Epub 2018 Dec 3. PMID: 30704685. 24. Tanner C.M., Kamel F., Ross G.W., et al. Rotenone, paraquat, and Parkinson’s disease // Environ Health Perspect. 2011. 119: 866–72. 25. Tysnes O.B., Storstein A. Epidemiology of Parkinson’s disease // Journal of Neural Transmission. 2017. 124. 901–905. doi:10.1007/s00702-017-1686-y 26. Wong S.L., Gilmour H., Ramage-Morin P.L. Parkinson's disease: Prevalence, diagnosis and impact // Health Rep. 2014 Nov. 25(11):10-4. PMID: 25408491. References: 1. Abdraimova S.O., Zharkinbekova N.A. Faktory riska razvitiya bolezni Parkinsona v Yuzhnom regione Kazakhstana [Parkinson's disease risk factors in the Southern region of Kazakhstan]. Nauka i Zdravookhranenie [Science & Healthcare]. 2023. 2 (T.25). pp. 95–103. doi 10.34689/SH.2023.25.2.014 [in Russian] 2. Informatsionnoe pis'mo 38/15 ot 29.03.2023 g. Turkestanskogo oblastnogo filiala Respublikanskogo Gosudarstvennogo predpriyatiya na prave khozyaistvennogo vvedeniya «Natsional'nyi Nauchnyi Tsentr Razvitiya Zdravookhraneniya imeni S. Kairbekovoi» Ministerstva Zdravookhraneniya Respubliki Kazakhstan [Information letter 38/15 dated March 29, 2023 of the Turkestan regional branch of the Republican State Enterprise on the right of economic administration “National Scientific Center for Health Development named after S. Kairbekova” of the Ministry of Health of the Republic of Kazakhstan]. [in Russian] 3. Fedorova N.V., Omarova S.M. Levodopa-indutsirovannye diskinezii pri bolezni Parkinsona: farmakoterapiya i neirokhirurgicheskoe lechenie [Levodopa-induced dyskinesias in Parkinson’s disease: pharmacotherapy and neurosurgical treatment]. Nervnye bolezni [Nervous diseases], 2017, no. 1, pp. 22-30. [in Russian]

Number of Views: 453

Key words: Parkinson's disease, clinical and demographic analysis, MDS UPDRS.

Category of articles: Original articles

Bibliography link

Abdraimova S.O., Arykbayeva G.M., Zharkinbekova N.A. Analysis of clinical and demographic indicators of patients with Parkinson's disease in the southern region of Kazakhstan // Nauka i Zdravookhranenie [Science & Healthcare]. 2024, (Vol.26) 1, pp. 31-37. doi 10.34689/SH.2024.26.1.004